Diffuse Large B-cell Lymphoma

Oncology
49
Pipeline Programs
26
Companies
50
Clinical Trials
6 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
6
20
1
6
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
838%
Monoclonal Antibody
838%
Small Molecule
314%
ADC
210%
+ 32 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
BRIUMVIApproved
ublituximab
Unknown Company
CD20-directed Cytolytic Antibody [EPC]intravenous2022
Roche
POLIVYApproved
polatuzumab vedotin
Roche
intravenous2019

Competitive Landscape

25 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
3 programs
1
1
POLIVY(Polatuzumab Vedotin)Phase 3ADC5 trials
GlofitamabN/AMonoclonal Antibody1 trial
Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)N/A1 trial
Active Trials
NCT07200375Recruiting300Est. Sep 2029
NCT02708732Completed91Est. Oct 2016
NCT07012980Not Yet Recruiting38Est. Jul 2026
+4 more trials
CT
3 programs
2
1
TQB2303Phase 31 trial
Anlotinib Hydrochloride CapsulesPhase 21 trial
TQ-B3525 tabletsPhase 21 trial
Active Trials
NCT04827004UnknownEst. Dec 2022
NCT04610970UnknownEst. Jun 2022
NCT03777085UnknownEst. Dec 2020
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
R-CHOPPhase 31 trial
Active Trials
NCT04231448Active Not RecruitingEst. Jun 2025
Innogene Kalbiotech
Innogene KalbiotechSingapore - Singapore
1 program
1
RTXM83Phase 3
mAbxience
mAbxienceSwitzerland - Lugano
1 program
1
RTXM83Phase 31 trial
Active Trials
NCT02268045Completed272Est. Jul 2017
Mabion
MabionPoland - Konstantynów
1 program
1
RituximabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02617485Completed143Est. Jan 2018
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
UblituximabPhase 2/3Monoclonal Antibody1 trial
Active Trials
NCT02793583Terminated710Est. Jul 2022
ADC Therapeutics
ADC TherapeuticsNJ - New Providence
5 programs
3
1
1
Loncastuximab TesirinePhase 21 trial
Loncastuximab TesirinePhase 1/21 trial
Loncastuximab TesirinePhase 11 trial
Loncastuximab Tesirine and DurvalumabPhase 1Monoclonal Antibody1 trial
Loncastuximab tesirinePhase 11 trial
Active Trials
NCT05660395RecruitingEst. Apr 2027
NCT03685344TerminatedEst. Oct 2020
NCT04974996WithdrawnEst. May 2027
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
4 programs
1
1
2
EpcoritamabPhase 2Monoclonal Antibody1 trial
EpcoritamabPhase 2Monoclonal Antibody1 trial
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisonePhase 1/21 trial
ABBV-525Phase 11 trial
Active Trials
NCT05618028Recruiting150Est. Jul 2029
NCT04663347Active Not Recruiting543Est. Sep 2027
NCT05451810Active Not Recruiting184Est. Mar 2027
+1 more trials
Karyopharm Therapeutics
3 programs
2
1
SelinexorPhase 21 trial
KPT-330Phase 11 trial
VenetoclaxPhase 1
Active Trials
NCT02471911CompletedEst. Oct 2021
NCT02227251RecruitingEst. Nov 2027
Genentech
GenentechCA - Oceanside
3 programs
1
2
Polatuzumab vedotinPhase 2ADC1 trial
bendamustinePhase 2
VenetoclaxPhase 11 trial
Active Trials
NCT03036904Completed31Est. Nov 2021
NCT05498220Active Not Recruiting5Est. Nov 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
2
AZD 2014Phase 21 trial
FostamatinibPhase 2Small Molecule1 trial
IbrutinibPhase 1/2Small Molecule1 trial
Active Trials
NCT02780830Withdrawn0Est. Apr 2019
NCT02752204Completed36Est. Feb 2020
NCT01499303Completed101Est. Oct 2013
Bayer
BayerLEVERKUSEN, Germany
2 programs
2
Ibritumomab TiuxetanPhase 25 trials
chemotherapy followed by ZevalinPhase 21 trial
Active Trials
NCT01448928Completed400Est. Jan 2018
NCT01479387Completed72Est. Feb 2011
NCT00607854Completed31Est. Nov 2011
+3 more trials
Sanofi
SanofiPARIS, France
2 programs
2
SAR3419Phase 21 trial
SAR3419Phase 21 trial
Active Trials
NCT01470456Completed50Est. Sep 2014
NCT01472887Completed61Est. Sep 2016
Takeda
TakedaTOKYO, Japan
1 program
1
AlisertibPhase 2Small Molecule1 trial
Active Trials
NCT00807495Completed48Est. Feb 2013
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
Axicabtagene CiloleucelPhase 2Cell Therapy1 trial
Active Trials
NCT07254754Recruiting45Est. Dec 2031
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
BlinatumomabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01741792Completed25Est. Sep 2015
Debiopharm
DebiopharmSwitzerland - Lausanne
1 program
1
Debio 1562Phase 21 trial
Active Trials
NCT02564744CompletedEst. Jun 2021
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
Rituximab, Temsirolimus, DHAP, intravenousPhase 21 trial
Active Trials
NCT01653067Unknown88Est. Jul 2018
Abbott
AbbottABBOTT PARK, IL
1 program
1
bendamustinePhase 21 trial
Active Trials
NCT01423539Withdrawn0Est. Feb 2014
Pfizer
PfizerNEW YORK, NY
2 programs
2
MaplirpaceptPhase 1/21 trial
maplirpaceptPhase 1/21 trial
Active Trials
NCT05626322Terminated6Est. May 2025
NCT05896163Active Not Recruiting24Est. Mar 2026
Antengene
AntengeneChina - Shanghai
1 program
1
ATG-010Phase 1/21 trial
Active Trials
NCT05265975TerminatedEst. Dec 2024
Novartis
NovartisBASEL, Switzerland
8 programs
4
AEB071Phase 11 trial
MAK683Phase 11 trial
TisagenlecleucelPhase 1Cell Therapy1 trial
TisagenlecleucelPhase 1Cell Therapy1 trial
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS DataN/ACell Therapy1 trial
+3 more programs
Active Trials
NCT06392763Completed602Est. Apr 2023
NCT06271369Completed613Est. Feb 2023
NCT05541328Completed169Est. Feb 2021
+5 more trials
Leman Biotech
Leman BiotechChina - Shenzhen
2 programs
2
Metabolically Armed CD19 CAR-T cellsPhase 1Cell Therapy1 trial
Metabolically Armed CD19 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT06120166RecruitingEst. Apr 2026
NCT05715606UnknownEst. May 2025
Celltrion
CelltrionKorea - Incheon
1 program
1
rituximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01534949Terminated1Est. Feb 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Chipscreen BiosciencesR-CHOP
Chia Tai TianQing Pharmaceutical GroupTQB2303
RochePolatuzumab Vedotin
MabionRituximab
mAbxienceRTXM83
BayerIbritumomab Tiuxetan
TG TherapeuticsUblituximab
RochePolatuzumab Vedotin
Gilead SciencesAxicabtagene Ciloleucel
RochePolatuzumab Vedotin
AbbVieEpcoritamab
GenentechPolatuzumab vedotin
AbbVieEpcoritamab
ADC TherapeuticsLoncastuximab Tesirine
Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride Capsules

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 4,610 patients across 50 trials

NCT04231448Chipscreen BiosciencesR-CHOP

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Start: May 2020Est. completion: Jun 2025
Phase 3Active Not Recruiting
NCT03777085Chia Tai TianQing Pharmaceutical GroupTQB2303

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Start: Jan 2019Est. completion: Dec 2020
Phase 3Unknown
NCT03274492RochePolatuzumab Vedotin

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Start: Nov 2017Est. completion: Apr 20261,000 patients
Phase 3Active Not Recruiting
NCT02617485MabionRituximab

MabionCD20 Compared to MabThera in Lymphoma Patients

Start: Dec 2015Est. completion: Jan 2018143 patients
Phase 3Completed
NCT02268045mAbxienceRTXM83

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Start: May 2013Est. completion: Jul 2017272 patients
Phase 3Completed
NCT00185393BayerIbritumomab Tiuxetan

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Start: Aug 2001Est. completion: Feb 2007414 patients
Phase 3Completed
NCT02793583TG TherapeuticsUblituximab

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Start: May 2016Est. completion: Jul 2022710 patients
Phase 2/3Terminated
NCT07012980RochePolatuzumab Vedotin

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

Start: Jun 2025Est. completion: Jul 202638 patients
Phase 2Not Yet Recruiting
NCT07254754Gilead SciencesAxicabtagene Ciloleucel

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Start: Nov 2024Est. completion: Dec 203145 patients
Phase 2Recruiting
NCT06071871RochePolatuzumab Vedotin

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Start: Aug 2024Est. completion: Jul 202899 patients
Phase 2Recruiting
NCT05660967AbbVieEpcoritamab

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Start: Mar 2023Est. completion: Jun 2026111 patients
Phase 2Active Not Recruiting
NCT05498220GenentechPolatuzumab vedotin

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Start: Feb 2023Est. completion: Nov 20265 patients
Phase 2Active Not Recruiting
NCT05451810AbbVieEpcoritamab

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Start: Aug 2022Est. completion: Mar 2027184 patients
Phase 2Active Not Recruiting
NCT05144009ADC TherapeuticsLoncastuximab Tesirine

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Start: Jun 2022Est. completion: Jan 2024
Phase 2Terminated
NCT04827004Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride Capsules

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Start: Apr 2021Est. completion: Dec 2022
Phase 2Unknown
NCT04610970Chia Tai TianQing Pharmaceutical GroupTQ-B3525 tablets

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Start: Jan 2021Est. completion: Jun 2022
Phase 2Unknown
NCT02564744DebiopharmDebio 1562

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Start: Jun 2016Est. completion: Jun 2021
Phase 2Completed
NCT02752204AstraZenecaAZD 2014

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Start: Oct 2015Est. completion: Feb 202036 patients
Phase 2Completed
NCT02227251Karyopharm TherapeuticsSelinexor

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start: Nov 2014Est. completion: Nov 2027
Phase 2Recruiting
NCT01653067Heidelberg PharmaRituximab, Temsirolimus, DHAP, intravenous

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Start: Sep 2012Est. completion: Jul 201888 patients
Phase 2Unknown
NCT01741792AmgenBlinatumomab

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start: Jul 2012Est. completion: Sep 201525 patients
Phase 2Completed
NCT01472887SanofiSAR3419

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Start: Jan 2012Est. completion: Sep 201661 patients
Phase 2Completed
NCT01499303AstraZenecaFostamatinib

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Start: Dec 2011Est. completion: Oct 2013101 patients
Phase 2Completed
NCT01470456SanofiSAR3419

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: Nov 2011Est. completion: Sep 201450 patients
Phase 2Completed
NCT01423539Abbottbendamustine

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Start: Oct 2011Est. completion: Feb 20140
Phase 2Withdrawn
NCT00807495TakedaAlisertib

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Start: Feb 2009Est. completion: Feb 201348 patients
Phase 2Completed
NCT00607854BayerIbritumomab Tiuxetan

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Start: Feb 2008Est. completion: Nov 201131 patients
Phase 2Completed
NCT01493479BayerIbritumomab Tiuxetan

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

Start: Jun 2007Est. completion: Nov 201576 patients
Phase 2Completed
NCT00440583Bayerchemotherapy followed by Zevalin

The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP

Start: Sep 2006Est. completion: May 201215 patients
Phase 2Completed
NCT00386321BayerIbritumomab Tiuxetan

Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

Start: Apr 2006Est. completion: Jan 201010 patients
Phase 2Terminated
NCT05896163Pfizermaplirpacept

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Start: Aug 2023Est. completion: Mar 202624 patients
Phase 1/2Active Not Recruiting
NCT05626322PfizerMaplirpacept

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Start: Aug 2023Est. completion: May 20256 patients
Phase 1/2Terminated
NCT05265975AntengeneATG-010

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Start: Apr 2022Est. completion: Dec 2024
Phase 1/2Terminated
NCT04663347AbbVierituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Start: Nov 2020Est. completion: Sep 2027543 patients
Phase 1/2Active Not Recruiting
NCT03677141RochePolatuzumab Vedotin

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Start: Mar 2019Est. completion: Oct 2023117 patients
Phase 1/2Completed
NCT03684694ADC TherapeuticsLoncastuximab Tesirine

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Start: Dec 2018Est. completion: Nov 2022
Phase 1/2Terminated
NCT06120166Leman BiotechMetabolically Armed CD19 CAR-T cells

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Start: Nov 2023Est. completion: Apr 2026
Phase 1Recruiting
NCT05660395ADC TherapeuticsLoncastuximab Tesirine

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Start: Aug 2023Est. completion: Apr 2027
Phase 1Recruiting
NCT05618028AbbVieABBV-525

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

Start: Apr 2023Est. completion: Jul 2029150 patients
Phase 1Recruiting
NCT05715606Leman BiotechMetabolically Armed CD19 CAR-T cells

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Start: Feb 2023Est. completion: May 2025
Phase 1Unknown
NCT04974996ADC TherapeuticsLoncastuximab tesirine

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

Start: Feb 2022Est. completion: May 2027
Phase 1Withdrawn
NCT03876028NovartisTisagenlecleucel

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Start: Jun 2019Est. completion: Nov 202110 patients
Phase 1Terminated
NCT03685344ADC TherapeuticsLoncastuximab Tesirine and Durvalumab

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Start: Feb 2019Est. completion: Oct 2020
Phase 1Terminated
NCT03630159NovartisTisagenlecleucel

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

Start: Oct 2018Est. completion: Jul 202112 patients
Phase 1Completed
NCT03036904GenentechVenetoclax

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Start: Feb 2017Est. completion: Nov 202131 patients
Phase 1Completed
NCT02900651NovartisMAK683

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Start: Oct 2016Est. completion: Oct 2024139 patients
Phase 1Terminated
NCT02780830AstraZenecaIbrutinib

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Start: Jun 2016Est. completion: Apr 20190
Phase 1Withdrawn
NCT02471911Karyopharm TherapeuticsKPT-330

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Start: Dec 2015Est. completion: Oct 2021
Phase 1Completed
NCT01534949Celltrionrituximab

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial

Start: Feb 2012Est. completion: Feb 20131 patients
Phase 1Terminated
NCT01402440NovartisAEB071

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Start: Nov 2011Est. completion: Apr 201415 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 4,610 patients
26 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)